PMID- 17951206
OWN - NLM
STAT- MEDLINE
DCOM- 20071129
LR  - 20151119
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 128
IP  - 5
DP  - 2007 Nov
TI  - Does using a higher cutoff for the percentage of positive cells improve the 
      specificity of HER-2 immunohistochemical analysis in breast carcinoma?
PG  - 825-9
AB  - This study was performed to determine whether using a 30% cutoff for the 
      proportion of HER-2+ cells would increase the specificity of HER-2 
      immunohistochemical analysis. Blinded to the HER-2 amplification status, 3 
      pathologists retrospectively reviewed HER-2-stained sections of breast carcinoma 
      and considered cases to be positive for protein overexpression (3+) using 3 
      cutoff levels, 10%, 30%, and 50%, for the proportion of cells with intense 
      uniform staining. Of 98 cases, 27 (28%) were positive by fluorescence in situ 
      hybridization (FISH), and 32 (33%), 28 (29%), and 26 (27%) were considered 
      positive for overexpression using cutoffs of 10%, 30%, and 50%, respectively. The 
      specificity values of HER-2 immunohistochemical analysis were 82%, 86%, and 87% 
      for the different cutoffs, and the concordance rates of 3+ cases with FISH were 
      59%, 64%, and 65%, for the cutoffs of 10%, 30%, and 50%, respectively. These 
      findings seem to somehow support the recently proposed American Society of 
      Clinical Oncology/College of American Pathologists guideline recommendations for 
      HER-2 testing; nevertheless further studies are suggested.
FAU - Hameed, Omar
AU  - Hameed O
AD  - Department of Pathology, University of Alabama School of Medicine, Birmingham 
      35294-6823, USA.
FAU - Chhieng, David C
AU  - Chhieng DC
FAU - Adams, Amy L
AU  - Adams AL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/*chemistry/diagnosis
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/*chemistry/diagnosis
MH  - Cell Count
MH  - Female
MH  - Guidelines as Topic
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - In Situ Hybridization, Fluorescence
MH  - Predictive Value of Tests
MH  - Receptor, ErbB-2/*analysis
MH  - Reproducibility of Results
MH  - Retrospective Studies
EDAT- 2007/10/24 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/10/24 09:00
PHST- 2007/10/24 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/10/24 09:00 [entrez]
AID - AV58510T10782547 [pii]
AID - 10.1309/L9HQHR0798FH0LQN [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2007 Nov;128(5):825-9. doi: 10.1309/L9HQHR0798FH0LQN.